effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital

ABSTRACT

ConditionCOVID-19 diseaese.
COVID-19, virus not identified;U07.2

InterventionIntervention 1 Intervention group 30 COVID-19 patients with inclusion criteria will be treated with 250 micro grams of betafron (Zifron Zist Darou Danesh) Subcutaneously every other day up to 10 days or 5 dosages in addition to antivirals including hydroxychloroquine 400 mg,bid stat. and Kaletra 2 tablet bid for 10 days. Intervention 2 Control group 30 COVID-19 patients will be treated only with antivirals including hydroxychloroquine 400 mg,bid stat and Kaletra 2 tablet bid for 10 days.

Primary outcome:Oxygenation. Timepoint daily. Method of measurement pulse oximetery.

CriteriaInclusion criteria respiratory rate> 24 / min
pao2 / Fio2< 300

Exclusion criteria Pregnancy
history of Sensitivity to interferon-beta 1 compounds (zifron)
History of advanced liver disease and liver enzymes three times normal
history of severe depression or suicidal thought